102
Participants
Start Date
October 12, 2016
Primary Completion Date
June 11, 2020
Study Completion Date
February 2, 2021
Vedolizumab Placebo
Vedolizumab placebo-matching IV infusion
Ciprofloxacin
Ciprofloxacin tablets
Vedolizumab
Vedolizumab IV infusion
UZ Leuven - University Hospital Gasthuisberg, Leuven
Charite Universitatsmedizin Berlin -Campus Virchow Klinikum, Berlin
Istituto Clinico Humanitas IRCCS, Rozzano
Asklepios Hospital Hamburg - West, Hamburg
University of North Carolina GI, Chapel Hill
Carolinas HealthCare System Digestive Health, Charlotte
CHU de Toulouse - Hopital Rangueil, Toulouse
Hospital Doctor Negrin, Las Palmas de Gran Canaria
CHU de Rennes - Hopital de Pontchaillou, Rennes
Azienda Ospedaliera di Padova, Padua
Azienda Ospedaliera S. Orsola-Malpighi, Bologna
CHU Saint Etienne - Hopital Nord, Saint-Priest-en-Jarez
Cleveland Clinic Foundation, Cleveland
Hospital Universitario y Politecnico La Fe, Valencia
CHRU Nancy Hopital de Brabois, Vandœuvre-lès-Nancy
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Northshore University HealthSystem, Evanston
University of Chicago Medical Center, Chicago
Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim
Praxis fuer Gastroenterologie, Drs. Ehehalt/ Helmstaedter, Heidelberg
Texas Digestive Disease Consultants, Southlake
University of Utah Health Sciences Center, Salt Lake City
Vanderbilt University Medical Center, Nashville
GIRI (GI Research Institute), Vancouver
Ottawa Hospital - General Campus, Ottawa
Mount Sinai Hospital, Toronto
Universitatsklinikum Jena, Jena
Policlinico Gemelli, Rome
Academic Medical Center, Amsterdam
Maastricht University Medical Center, Maastricht
St. Mark's Hospital, Harrow
Royal London Hospital, London
John Radcliffe Hospital, Oxford
Lead Sponsor
Takeda
INDUSTRY